Andrew Alexis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Andrew Alexis has a total of 205 co-authors. Here are the top co-authors by number of shared publications:
Seemal R. Desai
Innovative Dermatology, Plano, USA
4 shared publicationsAdrian O. Rodriguez
Nashville Skin Comprehensive Dermatology Center, Nashville, USA
3 shared publicationsAmy McMichael
Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, USA
3 shared publicationsDaphne Chan
Johnson & Johnson, Horsham, USA
3 shared publications- Jonathan Ian Silverberg
Department of Dermatology, The George Washington University School of Medicine and Health Sciences , Washington, DC
3 shared publications Olivia Choi
Johnson & Johnson, Horsham, USA
3 shared publications
Latest Publications
- 9 October 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
Dermal Fillers in Skin of Color: Safety Considerations, Cultural Perspectives, and Patient-Centered Approaches
BACKGROUND: Patients with skin of color make up a growing share of aesthetic dermatology practice, yet evidence guiding filler treatment in this population remains limited. OBJECTIVE: To review the evidence on dermal filler treatment in patients with skin of color, emphasizing safety, treatment planning, and patient-centered care. METHODS AND MATERIALS: A narrative review of PubMed/MEDLINE was performed, focusing on filler safety and efficacy in Fitzpatrick skin types (FST) IV-VI, biologic characteristics of skin of color, and population-specific aesthetic considerations. RESULTS: Hyaluronic acid fillers have the strongest evidence base in higher Fitzpatrick phototypes; biostimulatory fillers, particularly calcium hydroxylapatite, show favorable safety data, although evidence remains limited for poly- l -lactic acid. Key considerations include increased risk of postinflammatory hyperpigmentation, differences in recognizing vascular occlusion, and a theoretical, not clinically observed, predisposition to hypertrophic scarring and keloid formation. Treatment goals are often shaped by patient preferences regarding ethnic preservation and facial identity. CONCLUSION: Dermal filler treatment in patients with skin of color can be performed safely and effectively when guided by an understanding of melanin-rich skin biology, population-specific aging patterns, and patient-defined aesthetic goals; additional studies in higher Fitzpatrick phototypes are needed.
- 9 October 2026
- Published by Wolters Kluwer Health in Dermatologic Surgery
Dermal Fillers in Skin of Color: Safety Considerations, Cultural Perspectives, and Patient-Centered Approaches
BACKGROUND: Patients with skin of color make up a growing share of aesthetic dermatology practice, yet evidence guiding filler treatment in this population remains limited. OBJECTIVE: To review the evidence on dermal filler treatment in patients with skin of color, emphasizing safety, treatment planning, and patient-centered care. METHODS AND MATERIALS: A narrative review of PubMed/MEDLINE was performed, focusing on filler safety and efficacy in Fitzpatrick skin types (FST) IV-VI, biologic characteristics of skin of color, and population-specific aesthetic considerations. RESULTS: Hyaluronic acid fillers have the strongest evidence base in higher Fitzpatrick phototypes; biostimulatory fillers, particularly calcium hydroxylapatite, show favorable safety data, although evidence remains limited for poly- l -lactic acid. Key considerations include increased risk of postinflammatory hyperpigmentation, differences in recognizing vascular occlusion, and a theoretical, not clinically observed, predisposition to hypertrophic scarring and keloid formation. Treatment goals are often shaped by patient preferences regarding ethnic preservation and facial identity. CONCLUSION: Dermal filler treatment in patients with skin of color can be performed safely and effectively when guided by an understanding of melanin-rich skin biology, population-specific aging patterns, and patient-defined aesthetic goals; additional studies in higher Fitzpatrick phototypes are needed.
- Open Access
- 2 March 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (4) , 2031-2045
The Impact of Post-inflammatory Pigment Alteration After Psoriasis: Novel Data from the VISIBLE Study
Introduction Post-inflammatory pigment alteration (PIPA) in skin previously affected by psoriasis is an important, often neglected problem. PIPA has a disproportionate negative impact in people with skin of color. The phase 3b VISIBLE study evaluated guselkumab efficacy and safety in participants with skin of color and moderate-to-severe plaque psoriasis (cohort A) or moderate-to-severe scalp psoriasis (cohort B). Here we report results from exploratory assessments of the quality-of-life impact of pigmentation changes as psoriasis lesions resolve and long-term skin clearance is achieved and of correlations between dyspigmentation and clinical and patient-reported outcomes. Methods Randomized (3:1) participants received guselkumab 100 mg or placebo with crossover to guselkumab at week 16. Patient-reported impact of dyspigmentation on quality of life was assessed via Skin Discoloration Impact Evaluation Questionnaire (SDIEQ). Correlations between SDIEQ, Psoriasis Area and Severity Index (PASI), and Dermatology Life Quality Index (DLQI) were assessed. Pigmentation journeys were tracked using standard and cross-polarized photographs evaluated for erythema, pigmentation, and skin tone evenness. Results Across treatment and Fitzpatrick skin type groups (N = 205), mean SDIEQ scores decreased from 8.4–9.5 (moderate impact) at baseline to 1.3–1.9 (mild impact) at week 48. Photographic improvements in pigmentation were also observed. The majority of guselkumab-treated participants achieved clear or almost clear skin at week 48. In cohort A, mean percent PASI improvement from baseline was 94.9%; in cohort B mean percent Psoriasis Scalp Severity Index improvement was 94.6%. At week 48, correlation between SDIEQ and DLQI (r = 0.7456; p < 0.001) was stronger than between PASI and DLQI (r = 0.3345; p < 0.001). Conclusion Following treatment with guselkumab, most participants achieved clear or almost clear skin and substantial improvements in skin discoloration. Exploratory analyses showed SDIEQ improvements impacted quality of life more than PASI improvements, suggesting greater attention to PIPA is warranted in comprehensive psoriasis management, especially for patients with skin of color. ClinicalTrials.gov Identifier NCT05272150.
- 2 March 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (4) , 2031-2045
Open AccessThe Impact of Post-inflammatory Pigment Alteration After Psoriasis: Novel Data from the VISIBLE Study
Introduction Post-inflammatory pigment alteration (PIPA) in skin previously affected by psoriasis is an important, often neglected problem. PIPA has a disproportionate negative impact in people with skin of color. The phase 3b VISIBLE study evaluated guselkumab efficacy and safety in participants with skin of color and moderate-to-severe plaque psoriasis (cohort A) or moderate-to-severe scalp psoriasis (cohort B). Here we report results from exploratory assessments of the quality-of-life impact of pigmentation changes as psoriasis lesions resolve and long-term skin clearance is achieved and of correlations between dyspigmentation and clinical and patient-reported outcomes. Methods Randomized (3:1) participants received guselkumab 100 mg or placebo with crossover to guselkumab at week 16. Patient-reported impact of dyspigmentation on quality of life was assessed via Skin Discoloration Impact Evaluation Questionnaire (SDIEQ). Correlations between SDIEQ, Psoriasis Area and Severity Index (PASI), and Dermatology Life Quality Index (DLQI) were assessed. Pigmentation journeys were tracked using standard and cross-polarized photographs evaluated for erythema, pigmentation, and skin tone evenness. Results Across treatment and Fitzpatrick skin type groups (N = 205), mean SDIEQ scores decreased from 8.4–9.5 (moderate impact) at baseline to 1.3–1.9 (mild impact) at week 48. Photographic improvements in pigmentation were also observed. The majority of guselkumab-treated participants achieved clear or almost clear skin at week 48. In cohort A, mean percent PASI improvement from baseline was 94.9%; in cohort B mean percent Psoriasis Scalp Severity Index improvement was 94.6%. At week 48, correlation between SDIEQ and DLQI (r = 0.7456; p < 0.001) was stronger than between PASI and DLQI (r = 0.3345; p < 0.001). Conclusion Following treatment with guselkumab, most participants achieved clear or almost clear skin and substantial improvements in skin discoloration. Exploratory analyses showed SDIEQ improvements impacted quality of life more than PASI improvements, suggesting greater attention to PIPA is warranted in comprehensive psoriasis management, especially for patients with skin of color. ClinicalTrials.gov Identifier NCT05272150.
- Open Access
- 6 November 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (1) , 28-40
International Expert Consensus on Defining Skin of Color and Delivering Equitable Dermatologic Care
Dermatological practice faces significant challenges in meeting the needs of populations with skin of color (SOC). Patients with SOC face disparities, including misdiagnoses and inequitable treatment outcomes. This expert consensus sought to identify gaps in dermatologic care for these populations and to propose strategies to promote inclusivity. Classification systems for SOC and healthcare disparities were investigated by reviewing English language articles on the subject published in PubMed between 2019 and 2024. An international panel of multidisciplinary experts from four continents (America, Asia, Africa, and Europe) analyzed the findings and developed recommendations. There are limitations in the current skin type classification systems, and gaps persist for SOC populations in research, clinical trials, and education for both providers and patients. Proposed strategies to bridge these gaps include refining classification systems (Dermatology societies), advancing SOC‐specific research, enhancing education, and integrating artificial intelligence. Key recommendations from the panel focused on four areas: (1) Research: Achieve SOC numbers in clinical trials and publications that would be a reflection of local and global populations, publish new guidelines on key SOC‐related issues, and achieve representative authorship in the said clinical trials and publications; (2) Resources: Create a global library of SOC images for dermatological diseases; (3) Education: Provide training for healthcare professionals and scholarships for students worldwide to improve awareness and expertise; (4) Representation: Ensure SOC representation in images used for patient communication and educational materials.
- 6 November 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (1) , 28-40
Open AccessInternational Expert Consensus on Defining Skin of Color and Delivering Equitable Dermatologic Care
Dermatological practice faces significant challenges in meeting the needs of populations with skin of color (SOC). Patients with SOC face disparities, including misdiagnoses and inequitable treatment outcomes. This expert consensus sought to identify gaps in dermatologic care for these populations and to propose strategies to promote inclusivity. Classification systems for SOC and healthcare disparities were investigated by reviewing English language articles on the subject published in PubMed between 2019 and 2024. An international panel of multidisciplinary experts from four continents (America, Asia, Africa, and Europe) analyzed the findings and developed recommendations. There are limitations in the current skin type classification systems, and gaps persist for SOC populations in research, clinical trials, and education for both providers and patients. Proposed strategies to bridge these gaps include refining classification systems (Dermatology societies), advancing SOC‐specific research, enhancing education, and integrating artificial intelligence. Key recommendations from the panel focused on four areas: (1) Research: Achieve SOC numbers in clinical trials and publications that would be a reflection of local and global populations, publish new guidelines on key SOC‐related issues, and achieve representative authorship in the said clinical trials and publications; (2) Resources: Create a global library of SOC images for dermatological diseases; (3) Education: Provide training for healthcare professionals and scholarships for students worldwide to improve awareness and expertise; (4) Representation: Ensure SOC representation in images used for patient communication and educational materials.
- Open Access
- 6 November 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (1) , 41-56
International Expert Consensus on Knowledge Gaps in Care for Dermatologic Disorders in Skin of Color
Patients with skin of color (SOC) face unique dermatologic challenges that are often underrepresented in research and in dermatological education, creating critical gaps in care. We aimed to identify and explore key gaps in research and clinical management for SOC across four domains: skin diseases, hair disorders, photoprotection, and aesthetic procedures. An international panel reviewed articles retrieved from PubMed using the search terms “skin of color” or “skin of colour” in titles and abstracts from September 2019 to September 2024. Inflammatory skin diseases, including acne, atopic dermatitis, psoriasis, and rosacea, are common in SOC subjects, necessitating tailored diagnostic and therapeutic approaches due to unique clinical presentations and specific challenges such as post‐inflammatory hyperpigmentation and erythema detection. Pigmentary disorders such as melasma and acne‐induced hyperpigmentation significantly impact quality of life in SOC, requiring cautious treatment to avoid exacerbation, while the unregulated use of skin bleaching agents containing high‐potency corticosteroids can pose serious health risks. Skin cancer in SOC often presents at advanced stages with poorer outcomes due to lower awareness and unique clinical manifestations, resulting in delayed diagnosis. Hair disorders in SOC populations require tailored diagnostic and therapeutic approaches due to unique hair properties. Gaps in photoprotection education on SOC exacerbate pigmentary disorders and other dermatologic conditions, with limited research on effective sunscreens for this population. In aesthetic dermatology, misconceptions and knowledge gaps regarding the prevention of complications hinder access to safe and effective procedures for SOC subjects, compounded by inadequate diversity in clinical trials. Inclusive research, improved diagnostic accuracy, and customized procedures are needed to ensure equitable dermatologic care.
- 6 November 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (1) , 41-56
Open AccessInternational Expert Consensus on Knowledge Gaps in Care for Dermatologic Disorders in Skin of Color
Patients with skin of color (SOC) face unique dermatologic challenges that are often underrepresented in research and in dermatological education, creating critical gaps in care. We aimed to identify and explore key gaps in research and clinical management for SOC across four domains: skin diseases, hair disorders, photoprotection, and aesthetic procedures. An international panel reviewed articles retrieved from PubMed using the search terms “skin of color” or “skin of colour” in titles and abstracts from September 2019 to September 2024. Inflammatory skin diseases, including acne, atopic dermatitis, psoriasis, and rosacea, are common in SOC subjects, necessitating tailored diagnostic and therapeutic approaches due to unique clinical presentations and specific challenges such as post‐inflammatory hyperpigmentation and erythema detection. Pigmentary disorders such as melasma and acne‐induced hyperpigmentation significantly impact quality of life in SOC, requiring cautious treatment to avoid exacerbation, while the unregulated use of skin bleaching agents containing high‐potency corticosteroids can pose serious health risks. Skin cancer in SOC often presents at advanced stages with poorer outcomes due to lower awareness and unique clinical manifestations, resulting in delayed diagnosis. Hair disorders in SOC populations require tailored diagnostic and therapeutic approaches due to unique hair properties. Gaps in photoprotection education on SOC exacerbate pigmentary disorders and other dermatologic conditions, with limited research on effective sunscreens for this population. In aesthetic dermatology, misconceptions and knowledge gaps regarding the prevention of complications hinder access to safe and effective procedures for SOC subjects, compounded by inadequate diversity in clinical trials. Inclusive research, improved diagnostic accuracy, and customized procedures are needed to ensure equitable dermatologic care.
- Open Access
- 1 November 2025
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (1) , 189-198
Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks
Background The efficacy and safety of once-daily roflumilast foam 0.3%, a potent phosphodiesterase 4 inhibitor, has been demonstrated in patients with seborrheic dermatitis (SD). Objectives To evaluate long-term effects of roflumilast foam 0.3% in patients with SD. Methods A phase II, open-label trial (no. NCT04445987) was conducted in patients (aged ≥ 12 years) with SD who completed a prior roflumilast foam trial or were naïve to roflumilast and vehicle. Patients applied roflumilast foam 0.3% once daily to all affected areas, including the scalp, face, trunk, and intertriginous areas, for 24 or 52 weeks (during the course of the trial, the protocol was amended to extend the duration of treatment from 24 weeks to 52 weeks). The primary endpoints were occurrence of treatment-emergent adverse events (AEs); local tolerability and efficacy (via Investigator Global Assessment [IGA]) were also assessed. Results Overall, 400 patients participated, among whom 62 were enrolled for 52 weeks. AE rates were low, and ≤ 1.1% reported stinging sensation at the application site at each visit. Durable improvement in signs and symptoms of SD was observed at weeks 24 and 52, with 76.0% and 80.4% of patients, respectively, achieving an IGA of clear or almost clear. Conclusions Roflumilast foam 0.3% was well tolerated and improved and/or maintained improvements in signs and symptoms of SD for up to 52 weeks. ClinicalTrials.gov Listing NCT04445987.
- 1 November 2025
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (1) , 189-198
Open AccessLong-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks
Background The efficacy and safety of once-daily roflumilast foam 0.3%, a potent phosphodiesterase 4 inhibitor, has been demonstrated in patients with seborrheic dermatitis (SD). Objectives To evaluate long-term effects of roflumilast foam 0.3% in patients with SD. Methods A phase II, open-label trial (no. NCT04445987) was conducted in patients (aged ≥ 12 years) with SD who completed a prior roflumilast foam trial or were naïve to roflumilast and vehicle. Patients applied roflumilast foam 0.3% once daily to all affected areas, including the scalp, face, trunk, and intertriginous areas, for 24 or 52 weeks (during the course of the trial, the protocol was amended to extend the duration of treatment from 24 weeks to 52 weeks). The primary endpoints were occurrence of treatment-emergent adverse events (AEs); local tolerability and efficacy (via Investigator Global Assessment [IGA]) were also assessed. Results Overall, 400 patients participated, among whom 62 were enrolled for 52 weeks. AE rates were low, and ≤ 1.1% reported stinging sensation at the application site at each visit. Durable improvement in signs and symptoms of SD was observed at weeks 24 and 52, with 76.0% and 80.4% of patients, respectively, achieving an IGA of clear or almost clear. Conclusions Roflumilast foam 0.3% was well tolerated and improved and/or maintained improvements in signs and symptoms of SD for up to 52 weeks. ClinicalTrials.gov Listing NCT04445987.
- Open Access
- 21 October 2025
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (1) , 149-166
Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials
Background Differences in atopic dermatitis (AD) prevalence, clinical presentation, and pathophysiology have been reported in different ethnic/racial groups; however, clinical trial data for patients with skin of color are limited. Tralokinumab is a monoclonal antibody that specifically targets interleukin-13, a key driver of AD. Objectives To investigate the efficacy and safety of tralokinumab, and examine AD biomarker expression at baseline and week 16, by self-reported racial subgroup (Asian, Black, and White) in patients with moderate-to-severe AD. Methods Post hoc analyses were conducted by racial subgroup using data from four phase 3 trials: placebo-controlled parent trials ECZTRA 1, 2, and 3 and the open-label extension trial ECZTEND. Endpoints included Investigator’s Global Assessment (IGA) 0/1, 75% improvement in Eczema Area and Severity Index (EASI-75), and adverse events. In ECZTRA 1, serum and skin samples were analyzed for biomarker expression by immunoassay and Staphylococcus aureus (S. aureus) abundance by quantitative polymerase chain reaction (qPCR). Results A total of 1876 patients pooled from ECZTRA 1/2/3 (Asian/Black/White N = 407/134/1335) and 1392 patients from ECZTEND (Asian/Black/White N = 203/108/1081) were included. Baseline characteristics were largely balanced between treatment groups and racial subgroups, although AD severity was more moderate in Black patients and regional differences were observed. At week 16 of ECZTRA 1/2/3, tralokinumab improved efficacy outcomes, including IGA 0/1 and EASI-75, relative to placebo across all subgroups. Further improvements beyond week 16 were observed with continued tralokinumab treatment, including 78%, 88%, and 83% of Asian, Black, and White patients, respectively, achieving EASI-75 at week 56 of ECZTEND (corresponding to up to 2 years total tralokinumab treatment). At baseline, serum biomarker levels were elevated in Asian patients from Japan compared with other subgroups, while Asian patients from USA/Europe had lower S. aureus abundance, when adjusting for IGA. The safety profile of tralokinumab was comparable to placebo, and serious adverse events and adverse events leading to treatment discontinuation were rare, across racial subgroups. Conclusions Tralokinumab was well-tolerated and improved signs, symptoms, and biomarkers in patients with moderate-to-severe AD at 16 weeks across the racial subgroups studied, with further improvement in response rates up to 2 years of treatment. Clinical Trial Registration ClinicalTrials.gov identifiers: NCT03131648 (registered 24 April 2017), NCT03160885 (registered 18 May 2017), NCT03363854 (registered 01 December 2017), and NCT03587805 (registered 03 July 2018).
- 21 October 2025
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (1) , 149-166
Open AccessEfficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials
Background Differences in atopic dermatitis (AD) prevalence, clinical presentation, and pathophysiology have been reported in different ethnic/racial groups; however, clinical trial data for patients with skin of color are limited. Tralokinumab is a monoclonal antibody that specifically targets interleukin-13, a key driver of AD. Objectives To investigate the efficacy and safety of tralokinumab, and examine AD biomarker expression at baseline and week 16, by self-reported racial subgroup (Asian, Black, and White) in patients with moderate-to-severe AD. Methods Post hoc analyses were conducted by racial subgroup using data from four phase 3 trials: placebo-controlled parent trials ECZTRA 1, 2, and 3 and the open-label extension trial ECZTEND. Endpoints included Investigator’s Global Assessment (IGA) 0/1, 75% improvement in Eczema Area and Severity Index (EASI-75), and adverse events. In ECZTRA 1, serum and skin samples were analyzed for biomarker expression by immunoassay and Staphylococcus aureus (S. aureus) abundance by quantitative polymerase chain reaction (qPCR). Results A total of 1876 patients pooled from ECZTRA 1/2/3 (Asian/Black/White N = 407/134/1335) and 1392 patients from ECZTEND (Asian/Black/White N = 203/108/1081) were included. Baseline characteristics were largely balanced between treatment groups and racial subgroups, although AD severity was more moderate in Black patients and regional differences were observed. At week 16 of ECZTRA 1/2/3, tralokinumab improved efficacy outcomes, including IGA 0/1 and EASI-75, relative to placebo across all subgroups. Further improvements beyond week 16 were observed with continued tralokinumab treatment, including 78%, 88%, and 83% of Asian, Black, and White patients, respectively, achieving EASI-75 at week 56 of ECZTEND (corresponding to up to 2 years total tralokinumab treatment). At baseline, serum biomarker levels were elevated in Asian patients from Japan compared with other subgroups, while Asian patients from USA/Europe had lower S. aureus abundance, when adjusting for IGA. The safety profile of tralokinumab was comparable to placebo, and serious adverse events and adverse events leading to treatment discontinuation were rare, across racial subgroups. Conclusions Tralokinumab was well-tolerated and improved signs, symptoms, and biomarkers in patients with moderate-to-severe AD at 16 weeks across the racial subgroups studied, with further improvement in response rates up to 2 years of treatment. Clinical Trial Registration ClinicalTrials.gov identifiers: NCT03131648 (registered 24 April 2017), NCT03160885 (registered 18 May 2017), NCT03363854 (registered 01 December 2017), and NCT03587805 (registered 03 July 2018).
- Open Access
- 25 July 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (S2) , e70303
Real World Case Series: Integrated Skincare With Advanced RGN ‐6 Serum
Background: Skin aging is a multifactorial process with intrinsic and extrinsic factors that lead to visible signs of aging, including loss of skin elasticity, volume, dyspigmentation, wrinkles, fine lines, and dry and uneven skin. The advanced RGN‐6 serum is a patent‐pending, multi‐ingredient serum that has been developed to address 6 dimensions of skin regeneration and combat visible signs of aging. The six dimensions of skin regeneration include: (1) barrier re‐epithelialization, (2) redness and inflammation, (3) cellular energy stimulation, (4) elastin and collagen stimulation, (5) antioxidants, and (6) postinflammatory hyperpigmentation (PIH). To address these factors, the RGN‐6 serum contains six active ingredients: 1% eperuline, 0.2% ectoin, 10% glycorepair, 0.2% bioceramide 603, 3% acetyl tetrapeptide‐9, and 2% niacinamide. This multi‐ingredient serum works to simultaneously target the most common signs of aging. Aim: To provide detailed evidence for multiple integrated skincare regimens using the advanced RGN‐6 serum in facial rejuvenation. Methods: In this real‐world case series, 6 expert dermatologists with extensive experience in cosmetic and anti‐aging medicine shared and discussed patient cases of advanced RGN‐6 serum used in combination with energy‐based facial rejuvenation procedures in a subset of women with skin of color with Fitzpatrick skin types ranging from type 3 to type 6. Results: After the panel discussion, six patient cases were selected to best demonstrate the use of RGN‐6 serum postprocedure. Conclusion: The panel experts agreed that twice daily application of the RGN‐6 serum led to improved signs of redness, fine lines, and skin tone and evenness in all postprocedure patients.
- 25 July 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (S2) , e70303
Open AccessReal World Case Series: Integrated Skincare With Advanced RGN ‐6 Serum
Background: Skin aging is a multifactorial process with intrinsic and extrinsic factors that lead to visible signs of aging, including loss of skin elasticity, volume, dyspigmentation, wrinkles, fine lines, and dry and uneven skin. The advanced RGN‐6 serum is a patent‐pending, multi‐ingredient serum that has been developed to address 6 dimensions of skin regeneration and combat visible signs of aging. The six dimensions of skin regeneration include: (1) barrier re‐epithelialization, (2) redness and inflammation, (3) cellular energy stimulation, (4) elastin and collagen stimulation, (5) antioxidants, and (6) postinflammatory hyperpigmentation (PIH). To address these factors, the RGN‐6 serum contains six active ingredients: 1% eperuline, 0.2% ectoin, 10% glycorepair, 0.2% bioceramide 603, 3% acetyl tetrapeptide‐9, and 2% niacinamide. This multi‐ingredient serum works to simultaneously target the most common signs of aging. Aim: To provide detailed evidence for multiple integrated skincare regimens using the advanced RGN‐6 serum in facial rejuvenation. Methods: In this real‐world case series, 6 expert dermatologists with extensive experience in cosmetic and anti‐aging medicine shared and discussed patient cases of advanced RGN‐6 serum used in combination with energy‐based facial rejuvenation procedures in a subset of women with skin of color with Fitzpatrick skin types ranging from type 3 to type 6. Results: After the panel discussion, six patient cases were selected to best demonstrate the use of RGN‐6 serum postprocedure. Conclusion: The panel experts agreed that twice daily application of the RGN‐6 serum led to improved signs of redness, fine lines, and skin tone and evenness in all postprocedure patients.
- Open Access
- 22 July 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (9) , 2667-2682
Tapinarof Cream for Adults and Children with Atopic Dermatitis—Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials
Introduction Patients with atopic dermatitis (AD) and skin of color have heterogeneous presentations and treatment outcomes, however, they are underrepresented in trials. In the ADORING 1 and 2 phase 3, 8-week randomized trials, tapinarof cream 1% once daily (QD) demonstrated superior efficacy versus vehicle in adults and children down to age 2 years with AD. These analyses evaluate efficacy of tapinarof cream 1% QD stratified by race and Fitzpatrick skin type. Methods The primary endpoint was a Validated Investigator Global Assessment for Atopic Dermatitis™ (vIGA-AD™) score of 0 (clear) or 1 (almost clear) and ≥ 2-grade improvement from baseline at week 8. Secondary endpoints included achieving ≥ 75% improvement in Eczema Area and Severity Index (EASI75). Efficacy evaluations used race categories of Asian, Black or African American, and white, and Fitzpatrick skin types I–III and IV–VI. Results In ADORING 1 and 2, 407 and 406 patients were randomized to tapinarof or vehicle QD (7.3–17.0% Asian; 25.9–35.1% Black/African American 43.0–57.7% white), respectively. Across trials, > 50% had Fitzpatrick skin types IV–VI. Tapinarof demonstrated significant efficacy in adults and children. By race in both trials, the primary endpoint was met by consistently higher proportions treated with tapinarof than vehicle: Asian, 39.5–48.9% versus 3.7–18.5%; Black/African American, 43.1–47.0% versus 17.5–24.1%; white, 49.4–52.1% versus 12.2–14.5%, respectively. Similar, superior responses were reported across Fitzpatrick skin type groups with tapinarof versus vehicle: I–III, 44.8–49.9% versus 13.5–17.7%; IV–VI, 46.8–49.6% versus 15.3–19.5%. EASI75 responses were similarly higher and consistent with tapinarof versus vehicle. Adverse events were mostly mild or moderate, leading to low trial discontinuations (lower with tapinarof than vehicle). Conclusions Tapinarof demonstrated consistent efficacy and was well tolerated versus vehicle in a large, diverse population with AD, regardless of race or Fitzpatrick skin type. Trial registration Clinicaltrials.gov, NCT05014568, NCT05032859. Graphical Abstract avaliable for this article.
- 22 July 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (9) , 2667-2682
Open AccessTapinarof Cream for Adults and Children with Atopic Dermatitis—Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials
Introduction Patients with atopic dermatitis (AD) and skin of color have heterogeneous presentations and treatment outcomes, however, they are underrepresented in trials. In the ADORING 1 and 2 phase 3, 8-week randomized trials, tapinarof cream 1% once daily (QD) demonstrated superior efficacy versus vehicle in adults and children down to age 2 years with AD. These analyses evaluate efficacy of tapinarof cream 1% QD stratified by race and Fitzpatrick skin type. Methods The primary endpoint was a Validated Investigator Global Assessment for Atopic Dermatitis™ (vIGA-AD™) score of 0 (clear) or 1 (almost clear) and ≥ 2-grade improvement from baseline at week 8. Secondary endpoints included achieving ≥ 75% improvement in Eczema Area and Severity Index (EASI75). Efficacy evaluations used race categories of Asian, Black or African American, and white, and Fitzpatrick skin types I–III and IV–VI. Results In ADORING 1 and 2, 407 and 406 patients were randomized to tapinarof or vehicle QD (7.3–17.0% Asian; 25.9–35.1% Black/African American 43.0–57.7% white), respectively. Across trials, > 50% had Fitzpatrick skin types IV–VI. Tapinarof demonstrated significant efficacy in adults and children. By race in both trials, the primary endpoint was met by consistently higher proportions treated with tapinarof than vehicle: Asian, 39.5–48.9% versus 3.7–18.5%; Black/African American, 43.1–47.0% versus 17.5–24.1%; white, 49.4–52.1% versus 12.2–14.5%, respectively. Similar, superior responses were reported across Fitzpatrick skin type groups with tapinarof versus vehicle: I–III, 44.8–49.9% versus 13.5–17.7%; IV–VI, 46.8–49.6% versus 15.3–19.5%. EASI75 responses were similarly higher and consistent with tapinarof versus vehicle. Adverse events were mostly mild or moderate, leading to low trial discontinuations (lower with tapinarof than vehicle). Conclusions Tapinarof demonstrated consistent efficacy and was well tolerated versus vehicle in a large, diverse population with AD, regardless of race or Fitzpatrick skin type. Trial registration Clinicaltrials.gov, NCT05014568, NCT05032859. Graphical Abstract avaliable for this article.
- Open Access
- 15 July 2025
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 26 (5) , 1-15
Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable Study
Background Data are lacking to guide diagnosis and treatment in patients with skin of color and atopic dermatitis (AD), a population traditionally underrepresented in clinical trials. Objective The aim of this study was to evaluate the efficacy and safety of lebrikizumab in adults and adolescents with skin of color and moderate-to-severe AD. Methods In the open-label ADmirable trial, 90 adults and adolescents with moderate-to-severe AD, Fitzpatrick skin phototype IV–VI, and self-reported race other than White received lebrikizumab 250 mg subcutaneously every 2 weeks (Q2W), following a 500-mg loading dose at baseline and Week 2, for 16 weeks. From Week 16 to Week 24, responders, defined as patients with at least 75% improvement in Eczema Area and Severity Index (EASI 75) and/or Investigator’s Global Assessment (IGA) score of 0/1 with at least a 2-point improvement from baseline, received lebrikizumab every 4 weeks (Q4W); inadequate responders continued lebrikizumab Q2W. The primary endpoint was the percentage of patients achieving EASI 75 at Week 16. Secondary and exploratory efficacy endpoints and safety were assessed throughout. Data were analyzed as observed and using imputation, with Q2W and Q4W populations pooled for Weeks 16–24. Results Mean age at baseline was 40.7 years; 43.3% were female; and 43.3%, 24.4%, and 32.2% had Fitzpatrick skin phototypes IV, V, and VI, respectively. Baseline mean EASI and Pruritus Numeric Rating Scale (NRS) scores were 26.4 and 7.0, respectively; 68.9% of patients had moderate disease (IGA = 3). At Week 16 (number of patients with non-missing values [Nx] = 78), EASI 75, EASI 90 (≥ 90% improvement from baseline in EASI), and IGA 0/1 (IGA response of clear or almost clear) were achieved by 69.2%, 44.9%, and 44.9% of patients, respectively; for Pruritus NRS (Nx = 62), 58.1% of patients reported ≥ 4-point improvement. At Week 24 (Nx = 74) (pooled treatment arms), EASI 75, EASI 90, and IGA 0/1 were achieved by 78.4%, 47.3%, and 54.1% of patients, respectively. EASI 75 was achieved by 62.9%, 88.2%, and 95.5% of patients with Fitzpatrick skin phototype IV (Nx = 35), V (Nx = 17), and VI (Nx = 22), respectively, at Week 24. Most patients (64.4%) with baseline PDCA-Derm™-assessed hyperpigmented areas showed reduced hyperpigmentation at Week 24. Most treatment-emergent adverse events were mild or moderate in severity; none were serious or led to discontinuation. One case of conjunctivitis was reported. Conclusion In this first lebrikizumab study in patients with skin of color (Fitzpatrick skin phototype IV, V, and VI) and moderate-to-severe AD, lebrikizumab improved signs and symptoms of AD and confirmed its favorable safety profile. Trial Registration ClinicalTrials.gov Identifier: NCT05372419 (registered May 5, 2022).
- 15 July 2025
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 26 (5) , 1-15
Open AccessEfficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable Study
Background Data are lacking to guide diagnosis and treatment in patients with skin of color and atopic dermatitis (AD), a population traditionally underrepresented in clinical trials. Objective The aim of this study was to evaluate the efficacy and safety of lebrikizumab in adults and adolescents with skin of color and moderate-to-severe AD. Methods In the open-label ADmirable trial, 90 adults and adolescents with moderate-to-severe AD, Fitzpatrick skin phototype IV–VI, and self-reported race other than White received lebrikizumab 250 mg subcutaneously every 2 weeks (Q2W), following a 500-mg loading dose at baseline and Week 2, for 16 weeks. From Week 16 to Week 24, responders, defined as patients with at least 75% improvement in Eczema Area and Severity Index (EASI 75) and/or Investigator’s Global Assessment (IGA) score of 0/1 with at least a 2-point improvement from baseline, received lebrikizumab every 4 weeks (Q4W); inadequate responders continued lebrikizumab Q2W. The primary endpoint was the percentage of patients achieving EASI 75 at Week 16. Secondary and exploratory efficacy endpoints and safety were assessed throughout. Data were analyzed as observed and using imputation, with Q2W and Q4W populations pooled for Weeks 16–24. Results Mean age at baseline was 40.7 years; 43.3% were female; and 43.3%, 24.4%, and 32.2% had Fitzpatrick skin phototypes IV, V, and VI, respectively. Baseline mean EASI and Pruritus Numeric Rating Scale (NRS) scores were 26.4 and 7.0, respectively; 68.9% of patients had moderate disease (IGA = 3). At Week 16 (number of patients with non-missing values [Nx] = 78), EASI 75, EASI 90 (≥ 90% improvement from baseline in EASI), and IGA 0/1 (IGA response of clear or almost clear) were achieved by 69.2%, 44.9%, and 44.9% of patients, respectively; for Pruritus NRS (Nx = 62), 58.1% of patients reported ≥ 4-point improvement. At Week 24 (Nx = 74) (pooled treatment arms), EASI 75, EASI 90, and IGA 0/1 were achieved by 78.4%, 47.3%, and 54.1% of patients, respectively. EASI 75 was achieved by 62.9%, 88.2%, and 95.5% of patients with Fitzpatrick skin phototype IV (Nx = 35), V (Nx = 17), and VI (Nx = 22), respectively, at Week 24. Most patients (64.4%) with baseline PDCA-Derm™-assessed hyperpigmented areas showed reduced hyperpigmentation at Week 24. Most treatment-emergent adverse events were mild or moderate in severity; none were serious or led to discontinuation. One case of conjunctivitis was reported. Conclusion In this first lebrikizumab study in patients with skin of color (Fitzpatrick skin phototype IV, V, and VI) and moderate-to-severe AD, lebrikizumab improved signs and symptoms of AD and confirmed its favorable safety profile. Trial Registration ClinicalTrials.gov Identifier: NCT05372419 (registered May 5, 2022).
- Open Access
- 25 June 2025
- Published by American Medical Association (AMA) in JAMA Dermatology
Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones
Importance: Data and educational gaps in populations with skin of color contribute to racial and ethnic disparities in psoriasis treatment. Cohort A of the VISIBLE study includes participants with psoriasis who self-identify as belonging to a racial or ethnic category other than White, across the entire skin-tone spectrum.Objective: To evaluate efficacy, quality of life, and adverse event outcomes among participants with moderate to severe psoriasis and skin of color who received guselkumab, 100 mg, for up to 48 weeks.Design, Setting, and Participants: This ongoing phase 3b, randomized clinical trial at 39 sites in the US and Canada enrolled adults with skin of color and moderate to severe psoriasis (body surface area [BSA] ≥10%; Psoriasis Area and Severity Index [PASI] ≥12; Investigator’s Global Assessment [IGA] ≥3). Data were collected from August 2022 to June 2024.Interventions: Randomized participants (3:1) received guselkumab, 100 mg, at weeks 0 and 4, then every 8 weeks, or placebo with crossover to guselkumab at weeks 16 and 20, then every 8 weeks.Main Outcomes and Measures: Coprimary end points were IGA score of 0 or 1 (IGA 0/1) and PASI improvement of 90% or more (PASI 90) at week 16 (guselkumab vs placebo). Major secondary end points included IGA 0; PASI 100; percentage changes from baseline in PASI and BSA; changes from baseline in Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD) symptoms; and at least a 4-point reduction in PSSD itch.Results: Of 103 participants (77 randomized to guselkumab; 26 randomized to placebo), 94 (91.3%) completed 48 weeks of treatment. The mean (SD) age overall was 44.1 (12.9) years, and 74 participants (71.8%) were male. At week 16, coprimary end points were achieved by greater proportions of guselkumab- vs placebo-treated participants (IGA 0/1: 57 of 77 [74.0%] vs 0 of 26; P < .001; PASI 90: 44 of 77 [57.1%] vs 1 of 26 [3.8%]; P < .001); 25 of 77 (32.5%) vs 0 of 26 achieved IGA 0 (P < .001), and 23 of 77 (29.9%) vs 0 of 26 achieved PASI 100 (P = .002). DLQI and PSSD symptoms score least-squares mean changes from baseline were −12.1 (95% CI, −13.1 to −10.9) vs −2.5 (95% CI, −4.4 to −0.6) (P < .001), and −49.4 (95% CI, −54.0 to −44.9) vs −8.2 (95% CI, −15.8 to −0.6) (P < .001), respectively. A 4-point or greater reduction in PSSD itch score was achieved by 48 (66.7%) vs 4 (16.7%) participants with a baseline score of at least 4 (P < .001). Efficacy increased and was maintained through week 48, with guselkumab-randomized participants achieving mean percentage improvements in PASI and BSA of more than 94%, and more than 50% of participants achieving complete clearance. Infections were the most common adverse events in the guselkumab (16 [20.8%]) and placebo (3 [11.5%]) groups through week 16, predominantly upper respiratory tract infection and nasopharyngitis.Conclusions and Relevance: In this randomized clinical trial, after 3 doses of guselkumab, significant skin clearance and quality of life improvements were observed in this cohort of participants with moderate to severe psoriasis and skin of color across the range of objectively measured skin tones. Improvements increased and were maintained through week 48.Trial Registration: ClinicalTrials.gov Identifier: NCT05272150
- 25 June 2025
- Published by American Medical Association (AMA) in JAMA Dermatology
Open AccessGuselkumab for Moderate to Severe Psoriasis Across All Skin Tones
Importance: Data and educational gaps in populations with skin of color contribute to racial and ethnic disparities in psoriasis treatment. Cohort A of the VISIBLE study includes participants with psoriasis who self-identify as belonging to a racial or ethnic category other than White, across the entire skin-tone spectrum.Objective: To evaluate efficacy, quality of life, and adverse event outcomes among participants with moderate to severe psoriasis and skin of color who received guselkumab, 100 mg, for up to 48 weeks.Design, Setting, and Participants: This ongoing phase 3b, randomized clinical trial at 39 sites in the US and Canada enrolled adults with skin of color and moderate to severe psoriasis (body surface area [BSA] ≥10%; Psoriasis Area and Severity Index [PASI] ≥12; Investigator’s Global Assessment [IGA] ≥3). Data were collected from August 2022 to June 2024.Interventions: Randomized participants (3:1) received guselkumab, 100 mg, at weeks 0 and 4, then every 8 weeks, or placebo with crossover to guselkumab at weeks 16 and 20, then every 8 weeks.Main Outcomes and Measures: Coprimary end points were IGA score of 0 or 1 (IGA 0/1) and PASI improvement of 90% or more (PASI 90) at week 16 (guselkumab vs placebo). Major secondary end points included IGA 0; PASI 100; percentage changes from baseline in PASI and BSA; changes from baseline in Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD) symptoms; and at least a 4-point reduction in PSSD itch.Results: Of 103 participants (77 randomized to guselkumab; 26 randomized to placebo), 94 (91.3%) completed 48 weeks of treatment. The mean (SD) age overall was 44.1 (12.9) years, and 74 participants (71.8%) were male. At week 16, coprimary end points were achieved by greater proportions of guselkumab- vs placebo-treated participants (IGA 0/1: 57 of 77 [74.0%] vs 0 of 26; P < .001; PASI 90: 44 of 77 [57.1%] vs 1 of 26 [3.8%]; P < .001); 25 of 77 (32.5%) vs 0 of 26 achieved IGA 0 (P < .001), and 23 of 77 (29.9%) vs 0 of 26 achieved PASI 100 (P = .002). DLQI and PSSD symptoms score least-squares mean changes from baseline were −12.1 (95% CI, −13.1 to −10.9) vs −2.5 (95% CI, −4.4 to −0.6) (P < .001), and −49.4 (95% CI, −54.0 to −44.9) vs −8.2 (95% CI, −15.8 to −0.6) (P < .001), respectively. A 4-point or greater reduction in PSSD itch score was achieved by 48 (66.7%) vs 4 (16.7%) participants with a baseline score of at least 4 (P < .001). Efficacy increased and was maintained through week 48, with guselkumab-randomized participants achieving mean percentage improvements in PASI and BSA of more than 94%, and more than 50% of participants achieving complete clearance. Infections were the most common adverse events in the guselkumab (16 [20.8%]) and placebo (3 [11.5%]) groups through week 16, predominantly upper respiratory tract infection and nasopharyngitis.Conclusions and Relevance: In this randomized clinical trial, after 3 doses of guselkumab, significant skin clearance and quality of life improvements were observed in this cohort of participants with moderate to severe psoriasis and skin of color across the range of objectively measured skin tones. Improvements increased and were maintained through week 48.Trial Registration: ClinicalTrials.gov Identifier: NCT05272150